Physician profile
Jonathon Mark Bird
NPI 1568457463
$2,297.28
in general payments reported to CMS, 2019-2025
24 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $73.62 · 2021: $400 · 2022: $661 · 2023: $275 · 2024: $471 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,162.60 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $221.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $189.00 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $96.61 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $72.07 | 2021-2025 | Freestyle Libre 2, Freestyle Libre |
| Glaxosmithkline, LLC. | $70.14 | 2019-2024 | Bexsero, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $59.71 | 2019-2025 | |
| Apria Healthcare LLC | $51.80 | 2021 | |
| Tris Pharma INC | $43.01 | 2019 | |
| Allergan, INC. | $41.31 | 2019-2020 | |
| Exact Sciences Corporation | $37.42 | 2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $34.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $33.57 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $25.44 | 2022 | |
| Eisai INC. | $23.65 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $18.19 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.78 | 2024 | Voquezna |
| Collegium Pharmaceutical, INC. | $16.46 | 2025 | Jornay Pm |
| Genzyme Corporation | $16.11 | 2019 | |
| Amarin Pharma, INC. | $15.73 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.61 | 2022 | |
| Aimmune Therapeutics, INC. | $12.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.86 | 2019 | |
| Merck Sharp & Dohme LLC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.